GlassScriptPhysician profile
Douglas C Mcadams
NPI 1134356298
$506.53
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.95 · 2023: $139 · 2024: $193 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102.25 | 2024-2025 | |
| Eisai INC. | $84.24 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $57.93 | 2022-2024 | Austedo, Austedo Xr |
| Amgen INC. | $46.60 | 2024-2025 | Uplizna |
| Emd Serono, INC. | $46.43 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $29.74 | 2023 | |
| Tg Therapeutics, INC. | $24.96 | 2023 | |
| Horizon Therapeutics Plc | $24.69 | 2023 | Uplizna |
| Pfizer INC. | $21.22 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.18 | 2025 | Hyqvia |
| Ucb, INC. | $17.92 | 2025 | Rystiggo |
| Celgene Corporation | $17.66 | 2023 | Zeposia |
| Life Molecular Imaging LTD | $14.71 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mcadams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.